| All (n = 72) F45, M27 Follow up length median 25 weeks | Statin tolerant, taking statin (n = 30) F15, M15 Follow up length median 24 weeks | Statin intolerant (n = 42) F30, M12 Follow up length median 23 weeks |
---|---|---|---|
Flu-like myositis | 8 (10%) | 1 (3%) | 7 (17%) |
Respiratory tract infection/symptoms | 6 (8%) | 2 (7%) | 4 (9%) |
Inject site reaction | 4 (6%) | 2 (7%) | 2 (5%) |
Fatigue | 1 (1%) | Â | 1 (2%) |
Headache/mental acuity/mood | 2 (3%) | Â | 2 (5%) |
Urticaria/itchiness | 2 (3%) | Â | 2 (5%) |
G.I. symptom | 2 (3%) | Â | 2 (5%) |
Weight gain | 1 (1%) | Â | 1 (2%) |
Hair loss | 1 (1%) | Â | 1 (2%) |
Any adverse events | 22 (31%) | 5 (17%) | 17 (40%) |
No adverse events | 50 (69%) | 25 (83%) | 25 (60%) |